These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 3496089

  • 1. The 2',3'-dideoxyriboside of 2,6-diaminopurine selectively inhibits human immunodeficiency virus (HIV) replication in vitro.
    Balzarini J, Pauwels R, Baba M, Robins MJ, Zou RM, Herdewijn P, De Clercq E.
    Biochem Biophys Res Commun; 1987 May 29; 145(1):269-76. PubMed ID: 3496089
    [Abstract] [Full Text] [Related]

  • 2. Potent and selective activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside, 3'-fluoro-2,6-diaminopurine-2',3'-dideoxyriboside, and 3'-fluoro-2',3'-dideoxyguanosine against human immunodeficiency virus.
    Balzarini J, Baba M, Pauwels R, Herdewijn P, Wood SG, Robins MJ, de Clercq E.
    Mol Pharmacol; 1988 Mar 29; 33(3):243-9. PubMed ID: 3258404
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Investigations on the anti-HIV activity of 2',3'-dideoxyadenosine analogues with modifications in either the pentose or purine moiety. Potent and selective anti-HIV activity of 2,6-diaminopurine 2',3'-dideoxyriboside.
    Pauwels R, Baba M, Balzarini J, Herdewijn P, Desmyter J, Robins MJ, Zou RM, Madej D, De Clercq E.
    Biochem Pharmacol; 1988 Apr 01; 37(7):1317-25. PubMed ID: 3258516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Selective inhibition of human immunodeficiency virus (HIV) by 3'-azido-2', 3'-dideoxyguanosine in vitro.
    Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E.
    Biochem Biophys Res Commun; 1987 Jun 30; 145(3):1080-6. PubMed ID: 3649230
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of the 2-chloro analogues of 3'-deoxyadenosine, 2',3'-dideoxyadenosine, and 2',3'-didehydro-2',3'-dideoxyadenosine as potential antiviral agents.
    Rosowsky A, Solan VC, Sodroski JG, Ruprecht RM.
    J Med Chem; 1989 May 30; 32(5):1135-40. PubMed ID: 2785212
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.
    Haertle T, Carrera CJ, Wasson DB, Sowers LC, Richman DD, Carson DA.
    J Biol Chem; 1988 Apr 25; 263(12):5870-5. PubMed ID: 3258602
    [Abstract] [Full Text] [Related]

  • 13. 3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
    Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S, Vanderhaeghe H.
    J Med Chem; 1987 Aug 25; 30(8):1270-8. PubMed ID: 3497272
    [Abstract] [Full Text] [Related]

  • 14. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells.
    Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG, Fridland A.
    J Biol Chem; 1988 Oct 25; 263(30):15354-7. PubMed ID: 3262616
    [Abstract] [Full Text] [Related]

  • 15. Potentiating effect of ribavirin on the anti-retrovirus activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside in vitro and in vivo.
    Balzarini J, Herdewijn P, De Clercq E.
    Antiviral Res; 1989 Oct 25; 11(4):161-71. PubMed ID: 2545163
    [Abstract] [Full Text] [Related]

  • 16. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.
    Mitsuya H, Jarrett RF, Matsukura M, Di Marzo Veronese F, DeVico AL, Sarngadharan MG, Johns DG, Reitz MS, Broder S.
    Proc Natl Acad Sci U S A; 1987 Apr 25; 84(7):2033-7. PubMed ID: 2436223
    [Abstract] [Full Text] [Related]

  • 17. Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.
    Balzarini J, Kruining J, Wedgwood O, Pannecouque C, Aquaro S, Perno CF, Naesens L, Witvrouw M, Heijtink R, De Clercq E, McGuigan C.
    FEBS Lett; 1997 Jun 30; 410(2-3):324-8. PubMed ID: 9237655
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and anti-HIV activity of various 2'- and 3'-substituted 2',3'-dideoxyadenosines: a structure-activity analysis.
    Herdewijn P, Pauwels R, Baba M, Balzarini J, De Clercq E.
    J Med Chem; 1987 Nov 30; 30(11):2131-7. PubMed ID: 3499515
    [Abstract] [Full Text] [Related]

  • 19. 2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine.
    Masood R, Ahluwalia GS, Cooney DA, Fridland A, Marquez VE, Driscoll JS, Hao Z, Mitsuya H, Perno CF, Broder S.
    Mol Pharmacol; 1990 Apr 30; 37(4):590-6. PubMed ID: 2109183
    [Abstract] [Full Text] [Related]

  • 20. Selective inhibition of the reverse transcription of duck hepatitis B virus by binding of 2',3'-dideoxyguanosine 5'-triphosphate to the viral polymerase.
    Howe AY, Robins MJ, Wilson JS, Tyrrell DL.
    Hepatology; 1996 Jan 30; 23(1):87-96. PubMed ID: 8550054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.